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INTRODUCTION
1INTRODUCTION
“For all the happiness that mankind can gain
It is not in pleasure but in relief from pain”
- JOHN DYRDEN
“Pain, like pleasure is passion of the soul,
That is an emotion and not one of the senses”
- PLATO AND ARISTOTLE (375 B.C)
Pain is a fundamental biological phenomenon. The International
Association for the Study of pain has defined pain as an unpleasant
sensory and emotional experience associated with actual or potential
tissue damage. Pain is always underestimated and under treated. The
relief of pain during surgery is the main part of anaesthesia.
In 1784 James Moore used mechanistic concepts to promote
neural compression as a useful technique for the provision surgical
anaesthesia.
In 1855 Gadecke (German) isolated an alkaloid from leaves of
coca plant. In 1860 Albert Nieemann was successful in isolating and
naming the alkaloid from the leaves of erythroxylon coca.
Brachial plexus block is a popular and widely employed regional
nerve block technique for perioperative anesthesia and analgesia for
2surgery of the upper extremity. Regional nerve block avoids the
unwanted effect of the anesthetic drugs used during general anesthesia
and the stress of laryngoscopy and tracheal intubation.
Brachial plexus block is approached at the level of trunks and the
compact arrangement of trunks at supraclavicular level gives a high
success rate with minimal drug volume and a dense blockade. Hence the
supraclavicular approach is the method of choice for blocking the
brachial plexus.
William steward halsted first performed brachial plexus block in
1895. In 1911 Kulenkampff and Hirshel described the first percutaneous
brachial plexus block by supraclavicular and axillary routes
respectively.
Of  the various techniques the most widely practiced methods are
the classical technique described by Patrick, vertical plumb pop
technique described by  Brown, 1st  rib walk over technique described
by Bonica and Moore, and the subclavian perivascular technique
described by Winne and Colins.
Of the various local anesthetics used for brachial plexus block
lignocaine and bupivacaine are used most frequently in our set up.
3Adrenaline is added to the local anesthetics to prolong the duration of
action and to minimize the systemic absorption.
To prolong the duration of analgesia various drugs have been
studied as adjuvants to the local anesthetic solution. These adjuvant
drugs are ideally expected to prolong the analgesic effects without
causing any systemic side effects or prolonging motor blockade.
HISTORY
1. 1858 - Theory of pain was a separate and distinct sense was
definitely formulated by Mortiz S.Schiff.
2. 1884 - William Halsted and Alfred Hall – idea of injecting
cocaine into nerve trunk.
3. 1911 - G. Hirschel performed first percutaneous axillary
brachial plexus block.
4. 1911 - D.Kulenkampff performed supraclavicular brachial
plexus block.
5. 1943 - Lidocaine was synthesized by Lofgreen and
Lundquvisit
6. 1956 - Bupivacaine synthesized by Ekenstam
7. 1963 - Bupivacaine introduced clinical practice by Telivuo
8. 1965 - Melzock and Walts propounded the Gate Control
Theory of pain.
AIM OF THE
STUDY
4AIM OF THE STUDY
Aim of the study is to evaluate the following observations in
patients receiving either dexamethasone or the placebo as an adjuvant to
local anesthetic mixture in supraclavicular brachial plexus block.
1. Onset of sensory blockade.
2. Onset of motor blockade.
3. Quality of anesthesia.
4. Duration of sensory blockade.
5. Duration of motor blockade.
6. Hemodynamic changes.
7. Complications.
5ANATOMY OF THE BRACHIAL PLEXUS
THE BRACHIAL PLEXUS:
Brachial Plexus is one of the most commonly used peripheral
nerve blocks in clinical practice. So knowledge of the formation of the
brachial plexus and of its distribution is absolutely essential for the
effective use of brachial plexus block for surgeries of the upper limb.
Absolute familiarity with the Vascular, Muscular and fascial
relationship of the brachial plexus throughout its formation and
distribution is equally essential for the mastery of various techniques of
brachial plexus anaesthesia.
In its course from the intervertebral foramina to the upper arm,
the fibres that constitute the plexus are composed consecutively of roots,
trunks, cords, divisions and terminal nerves which are formed through a
complex process of combining, dividing, recombining and finally
redividing.
FORMATION OF THE PLEXUS:
ROOTS:
The plexus  is  formed by  the  anterior  primary  rami  of  5th  to  8th
cervical plexus together with the bulk of the 1st thoracic nerve (C8-T1).

6In addition, there is frequently a combination from C4 to the 5th cervical
roots and another below the T2 to the 1stthoracic nerve. Occasionally the
plexus is mainly derived from C4-C8 (prefixed plexus) or from C6-T2
(post fixed plexus).
TRUNKS:
The five roots of the brachial plexus emerge from the
intervertebral foramina. They lie in the gutter between the anterior and
posterior tubercles of the corresponding transverse process. All five
roots then become sandwiched between Scalenus anterior and Scalenus
medius. Here the roots of C5 and C6 unite into the upper trunk, the root
of C7 continues as the middle trunk and those of C8 and T1 into the
lower trunk. Each trunk divides behind the clavicle, into anterior and
posterior divisions which unite in the axilla to form cords.
CORDS:
The six divisions stream into axilla and there join up into three
cords; lateral, medial and posterior. These cords are composed as
follows:
7The union of the anterior divisions of the Upper and middle
trunks form the lateral cord. The medial cord represents the continuation
of the anterior division of the lower trunk. The posterior cord comprises
of the posterior divisions of all the three trunks.
The composition of brachial plexus can be summarised as
follows:
1. Five roots (between the scalene muscles) - the anterior primary
rami of C5-C8 and T1.
2. Three trunks (in the posterior triangle)
a) Upper trunk C5 and C6
b) Middle trunk C7 alone
c) Lower trunk C8 and T1
3. Six divisions (behind the Clavicle) Each trunk divides into an
anterior and posterior division.
4. Three cords (within the axilla)
a. Lateral Cord - the fused anterior divisions of the upper and
middle trunks C5-C7
8b. Medial Cord - the anterior division of the lower
trunk C8-T1
c. Posterior Cord formed by the union of the posterior
divisions of all three trunks C5-T1
RELATIONS OF THE BRACHIAL PLEXUS:
ROOTS:
Lie between the Scalenus anterior and Scalenus medius. The roots
of the Plexus lie above the second part of the subclavian artery.
TRUNKS:
In the Posterior triangle, the trunks of the plexus invested in a
sheath of prevertebral fascia, are superficially placed, being covered by
skin, platysma and deepfascia.
The upper and middle trunks lie above the subclavian artery as
they stream across the first rib, but the lower trunk lie behind the artery
and may groove the rib immediately posterior to the subclavian groove.
DIVISIONS:
At the lateral border of the first rib, the trunks bifurcate into
divisions which are situated behind the clavicle, subclavius muscle and
the suprascapular vessels.
9CORDS:
The cords are formed at the apex of the axilla and become
grouped around the axillary artery.
THE INTERSCALENE SHEATH:
As the roots emerge in the groove between the transverse process
of the tubercle, they lie in a fibro fatty space between two layers of
fibrinous sheath.
Posterior Sheath from the posterior tubercles cover the front of
the medius, anterior sheath from anterior tubercles cover the posterior
aspect of the Scalenus anterior. The sheath extends into the axilla around
the plexus.
Significance of this space is that the local anaesthetic can be
injected to produce block at various sites by interscalene, subclavian
perivascular or the axillary approach.
SYMPATHETIC SUPPLY:
Close to the emergence the 5th and 6th Cervical nerves receive a
grey ramus from the middle cervical sympathetic ganglion. The 7th and
10
8th cervical nerves each receive a grey ramus from the inferior cervical
ganglion and from T1ganglion
BRANCHES:
Branches are given off from roots, trunks and cords.
1. Branches from the roots:
a) Nerve to the serratus anterior C5, C6 and C7
b) Muscular branches to
- Longus cervices C5 - C8
- Three Scalene C5 - C8
- Rhomboids C5
c) Twig to the Phrenic nerve C5
2. Branches from the trunks:
a) Suprascapular nerve C5-C6
b) Nerve to subclavius C5-C6
3. Branches from the Cords:
a) Lateral Cord
- Lateral Pectoral nerve C5-C7
- Lateral head of median nerve C5-C7
- Musculocutaneous nerve C5-C7
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b) Medial Cord
- Medial Pectoral nerve C8 - T1
- Medial head of median nerve C8 - T1
- Medial Cutaneous nerve of arm C8 - T1
- Medial Cutaneous nerve of forearm C8 - T1
- Ulnar nerve of arm C7, C8 - T1
c) Posterior Cord
- Upper Subscapular nerve C5-C6
- Lower Subscapular nerve C5-C6
- Nerve to latissimus dorsi C6, C7, C8
- Axillary nerve C5-C6
- Radial nerve C5, C6, C7, C8, T1
ANATOMIC CONSIDERATIONS OF THE INTERSCALENE
SPACE:
The roots of the brachial plexus, after leaving the transverse
process of the corresponding cervical vertebrae, descend in between the
scalenus anterior and medius in the posterior triangle of the neck.
Scalenus anterior arises from the anterior tubercles of the
transverse processes of C3- C6 Vertebrae. It is inserted into the scalene
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tubercle on the inner border of  the first  rib.  The muscle lies  anterior  to
the plexus and at its insertion lies anterior to the subclavian artery which
separates the plexus from its insertion. Scalenus medius arises from the
posterior tubercles of the six lowest cervical vertebrae and is inserted
into the upper surface of the first rib behind the groove made by the
brachial plexus and the subclavian artery. Thus the plexus lies in front of
the muscle.
The first rib lies in an almost horizontal plane being inclined
slightly downwards and forwards. It passes below the clavicle at about
the junction of its inner and middle thirds. The upper surface of first rib
has two transverse grooves - an anterior one for the subclavian vein and
a posterior one for the subclavian artery and the lowest trunk of the
brachial plexus. On the inner border between the grooves is the scalene
tubercle.
Brachial line runs in a straight line from the transverse process of
the C6 vertebra to the axillary artery in the axilla. It runs inferolaterally
at an angle of 45degree from the horizontal plane and slightly forwards
at 15 degree.
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Techniques of Brachial Plexus Block:
Surgical anaesthesia of the upper extremity and shoulder can be
achieved following neural blockade of the brachial plexus at various
sites. The various approaches that can be used for this blockade is as
follows:
i) Interscalene approach
ii) Supraclavicular approach
a) Classic approach
b) Plumb bob technique
c) Supraclavicular Perivascular technique
iii) Axillary approach
iv) Infraclavicular approach
1. INTERSCALENE BRACHIAL PLEXUS BLOCK:
In this technique plexus is blocked at the level of the C6 vertebra.
By standing at the side of the patient and after locating the interscalene
groove, an intradermal wheal is raised at the point of needle insertion
which  is  at  the  level  of  the  cricoid  cartilage.  A  22gauge  3.5  cm  short
bevel needle is inserted “at right angles to the skin in all planes” i.e.
dorsal to the horizontal planes. The needle is advanced slowly until
14
paraesthesia sought in the shoulder or a nerve stimulator is used to
evoke contractions in the deltoid or biceps brachialis muscle.20 -40 ml
of local anaesthetic injected after repeated aspiration to detect
inadvertent entry into vertebral artery or dural cuff.
COMPLICATIONS:
1. Subarachnoid injection
2. Epidural blockade
3. Intravascular Injection
4. Pneumothorax
5. Phrenic nerve block
2. SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK:
A. CLASSICAL SUPRACLAVICULAR BLOCK OF
KULENKAMPFF:
In the classic approach, the needle insertion site is 1 cm superior
to the clavicular mid point. The needle is inserted in a plane parallel to
the patient neck and head. The needle will contact the rib at a depth of 3
to 4 cm. The needle is walked over the rib until paraesthesia is elicited.
After careful aspiration the local anaesthetic is injected.
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B. PLUMB BOB SUPRACLAVICULAR BLOCK:
The brachial  plexus at  the level  of  the first  rib lies  posterior  and
cephalic to the subclavian artery. Once this skin mark has been placed
immediately  superior  to  the  clavicle  at  the  lateral  border  of  the
sternomastoid muscle as it is inserted into the clavicle, the needle is
inserted at a 90 degree angle to the table top.
The local anaesthetic is injected after eliciting paraestehsia. The
name Plumb bob was chosen for this technique because if one suspends
a Plumb bob over the entry site, needle inserted through that point will
result in contact with the brachial plexus in most patients.
C. SUBCLAVIAN PERIVASCULAR TECHNIQUE OF
WINNIE AND COLLINS:
The interscalene groove is palpated at its most inferior point,
which is just posterior to the subclavian artery pulse. The needle is
directed just above and posterior to the subclavian pulse and directed
caudally at a flat angle against the skin. The needle is advanced until
paraesthesia is elicited and the local anaesthetic is injected after careful
aspiration.
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COMPLICATIONS:
1. Pneumothorax
2. Horner’s syndrome
3. Phrenic nerve block
4. Haemothorax and Haematoma formation.
3. INFRACLAVICULAR TECHNIQUE:
This is the preferred technique for the surgeries of elbow and
lower arm because spread of local anaesthetic is kept below the clavicle.
This  technique  blocks  the  brachial  plexus  at  the  level  of  cords.  The
needle is inserted 1 inch beneath the midpoint of the clavicle. It is then
directed laterally from this site at a 45 degree angle away from the chest
wall and towards the humeral head or the coracoid process. Once
paraethesia is elicited, the local anaesthetic is injected.
COMPLICATIONS:
1. Pneumothorax
2. Haemothorax
3. Chylothorax with a left side block
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4. AXILLARY BRACHIAL PLEXUS BLOCK:
The pulsations of the axillary artery are best felt high in the axilla
between the coracobrachialis and pectoralis major muscle. The needle is
inserted just superior to the artery until the resistance of the fascial
sheath is felt and a pop indicated the correct needle placement.
COMPLICATIONS:
1. Intra arterial Injection.
2. Post Operative neuropathy
3. Hematoma and Infection.
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PHARMACOLOGY OF LIGNOCAINE
Lignocaine was synthesized in 1943 in Swedan by Lofgren and
was introduced into clinical practice in 1948.
DESCRIPTION
Lignocaine hydrochloride is 2-diethylamino-aceto-2'6xylilide
hydrochloride monohydrate. It appears as a white crystalline powder
which is odourless. It is very soluble in water, freely soluble in
chloroform and in ethanol and is practically insoluble in ether.
Molecular formula - C14H22 N20 Hcl.H20
Molecular weight - 288.8
Lignocaine hydrochloride injection is a sterile, isotonic solution
containing lignocaine hydrochloride B.P., 1% or 2%, and sodium
chloride, B.P., in water for injection. Lignocaine is a weak base with
amphiphillic property. A hydrophilic amine on one side and a lipophillic
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lipophillic form (B+), reionises in the axoplasm and approaches the LA
receptor through the intracellular mouth of the channel. It is the cationic
form of local anaesthetic (BH+), which primarily binds to the LA
receptor. The receptor has higher affinity or is more accessible to local
anaesthetic in the activated state compared to the resting state. Binding
of LA to its receptor stabilizes the channel in the inactive state and thus
reduces the probability of channel opening.
Action of receptors within the sodium channel accounts for 90%
of nerve blocking effect. Nonspecific membrane expansion accounts for
the  remaining  10%  of  the  action  and  is  analogous  to  the  electrical
stabilization produced by a number of non-polar, purely lipid solvable
substances such as barbiturates, general anaesthetics and benzocaine.
PHARMACOLOGICAL ACTION:
1. LOCAL - Minimal local irritant action and blocks
sensory nerve endings, nerve trunks, neuro-
muscular junction, ganglionic receptors.
2. REGIONAL - Autonomic fibers are generally more
susceptible than somatic fibers. Among the
21
somatic afferents, the order of blockade is
pain, temperature, touch ,deep pressure.
3. SYSTEMIC - Effect is mainly on CVS or CNS.
CVS : In cardiac tissue, a therapeutic serum concentration (1.5 to
6. micrograms / ml) of lignocaine will produce the following effects:
a. Depression of slow spontaneous depolarization (phase 4),
that is the automaticity of isolated, non-polarised purkinjee fibres, while
having little effect on conduction velocity, membrane responsiveness or
cardiac output. Automaticity induced by stretch, hypoxia or
catecholamines can also be suppressed by lignocaine.
b. Shortening of action potential period and effective
refractory period of purkinjee and ventricular cells.
Thus it has a stabilizing effect on cell membrane of cardiac tissue.
It also stabilizes aberrant conduction.
CNS : Low plasma concentration of LA are likely to produce
numbness  of   tongue  and  circumoral  tisses.  As  plasma  concentration
increases it crosses blood-brain-barrier and produces restlessness,
vertigo, tinitus and difficulty in focusing. Then slurred speech and
22
skeletal muscle twitching occur. Lignocaine causes drowsiness before
seizures. Seizures are classically followed by CNS depression, which
may be accompanied by hypotension and apnoea.
PHARMACOKINETICS
Following IV injection, the blood level of lignocaine declines
with a half-life of 7 to 10 mins, within the first hour due to rapid
distribution into various tissues including the heart. After this initial
phase, the half-life is 90 to 120 mins (metabolism and excretion).
Absorption is slow in regional anaesthesia.
METABOLISM AND EXCRETION
The principle metabolic pathway of lignocaine is oxidative
dealkylation in the liver to mono ethyl glycinexylidine following by
hydrolysis of this metabolite to xylidine. Mono ethyl glycinexylidine
has approximately 80% of the activity of lignocaine for protecting
against cardiac dysrhythmias. This metabolite has a prolonged
elimination half time. Xylidine has approximately 10% of the activity of
lignocaine.
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Hepatic disease or decrease in hepatic flow, which may occur
during general anaesthesia, decreases the rate of metabolism of
lignocaine. Excretion is through the kidneys. Approximately 90% of the
dose is excreted as metabolites and less than 10% is excreted unchanged
in the urine.
DOSAGE
For regional anesthesia: 3mg/kg, with adrenaline 7mg/kg. For
cardiac arrythmias, therapeutic serum concentration of lignocaine is 5 to
20 micromol/L or 1.5 to 6.0 micrograms/ ml. A single intravenous dose
of 1mg/kg should be given over 1 to 2 mins, to obtain therapeutic blood
levels rapidly. The initial effect will occur in 2 to 4 mins, and may last
as long as 20 mins. This should be followed within 10 mins, by a
continuous infusion at the rate of 2 to 4 mgs/min. The initial dose may
be repeated by two more injections at 15 to 20 min intervals to maintain
therapeutic blood levels but no more than 300mg of lignocaine should
be administered within a 1 hr period. Since it has a very narrow
therapeutic window, infusion should promptly stopped when there is an
undue prolongation of PR interval or QRS complex.
To attenuate the cardiovascular stress response to intubation,
lignocaine 1.5mg/kg IV 3 min prior to laryngoscope should be given.
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ADVERSE EFFECTS /TOXICITY:
Due to high plasma levels as a result of excessive dosage, rapid
absorption, delayed elimination or inadvertent IM injection during local
anaesthetic use.
1. CNS: Lightheadedness, disorientation, confusion, psychois,
nervousness, agitation, drowsiness, euphoria, tinnitus, blurred
vision, slurred speech, numbness, twitching, tremors, convulsions,
unconsiousness, seizures, coma, respiratory depression and
arrest.
2. CVS: Hypotension, CVS collapse, arrhythmias, heart block and
bradycardia which may lead to cardiac arrest. Meth-
hemoglobineamia may occur following IV administration.
3. HYPERSENSITIVITY: Rare with lignocaine.
4. NEUROLOGICAL SYSTEM : Persistent anaestheisa,
paresthesia, weakness, paraplegia of lower extremeities and loss
of sphincter control may occur.
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PRECAUTIONS
The safety and effectiveness of lignocaine depends upon proper
dosage, correct technique, adequate precautions and readiness for
emergencies.
1. Lignocaine should be given cautiously in patients with severe
bradycardia, cardiac conduction disturbances, severe digitalis
intoxication, severe shock and hypovolemia.
2. Serum Potassium level should be normalized prior to
administration of lignocaine as antiarrhythmic drugs may be
ineffective in hypokalemic patients.
DRUG INTERACTIONS
Propanolol and metaprolol reduce the metabolism of
intravenously administered lignocaine. It is possible that this effect will
be repeated with other beta - adrenergic blockers.
1. Phenytoin, phenobarbitone, primidone and carbamazapine
appears to enhance the metabolism of lignocaine, possible due to
an induction of microsomal enzyme.
2. Lignocaine prolongs the duration of suxamethonium.
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PHARMACOLOGY  OF  BUPIVACAINE
Bupivacaine is an amide linked local anaesthetic. It is a
hydrochloride salt of 1-butyl-N-(2, 6-dimethylphenyl) piperidine-2-
carboxamide and is presented as a racemic mixture.
It was synthesized by Ekenstam in 1957.First report of its use was
published in 1963 by Telivuo. It is derived from Mepivacaine and is
very stable compound and may be autoclaved repeatedly.
Pka - 8.1
Molecular weight - 288
Protein binding -  95%
Lipid solubility - 28
Elimination half life - 210 minutes
Toxic plasma concentration  - >1.5?g/ml
Approximate duration of action - 175minutes
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Availability:
Ampoules
- 0.5% Bupivacaine hydrochloride with dextrose(Heavy) 4cc
- 0.5% Bupivacaine hydrochloride (plain)
Vials
- 0.25% and 0.5% Bupivacaine hydrochloride 20cc
Dosage
- Maximum dosage 3mg/kg body weight.
Uses:
- Spinal anaesthesia
- Epidural anaesthesia
- Caudal anaesthesia
- Continuous epidural anaesthesia
- Peripheral nerve block
Onset time and duration of action
Site of action         Onset (minutes)     Duration (minutes)
Intrathecal                       5                             90-120
Epidural                       15-20                         165-225
Brachial plexus            10-20                         600
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Pharmacokinetics:
Once injected intrathecaly, it gets absorbed by the nerve rootlets
and results in the desired effect. It is rapidly absorbed from the site of
injection, but the rate of absorption depends on the vascularity at the site
and presence of vasoconstrictors.
High lipid solubility of bupivacaine makes it easy for nerve and
vascular tissue penetration. 80-95% of the absorbed bupivacaine binds
to the plasma proteins.
Distribution:
1. Rapid distribution phase: (?)
In this phase the drug is distributed to highly vascular region,
t½ of ? - being 2. 7 minutes.
2. Slow disappearance phase: (?)
In this phase the drug is distributed to slowly equilibrating tissues,
t1/2 of ? being 28minutes.
3. Biotransformation and excretion phase: (?)
T1/2 of ? is 3.5hours. Clearance is 0.47 litre/minute.
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Biotransformation:
Possible pathways of metabolism of bupivacaine include
earomatic hydroxylation and conjugation. Only the N-dealkylated
metabolite, N-desbutyl bupivacaine has been measured in blood (or)
urine after epidural (or) spinal anaesthesia. Alpha-1 acid glycoprotein is
the most important plasma protein binding site of bupivacaine and its
concentration is increased by many clinical situations including post
operative trauma.
Excretion:
It is through the kidney, 4-10% of the drug is excreted unchanged.
Mode of Action:
a) Site of action:
i) Peripheral nerve rootlet , fine nerve filaments
ii) The spinal nerve rootlet fine nerve filaments having a large
surface area are exposed to the local anaesthetics
iii) Posterior and lateral aspects of the spinal cord itself.
b) Sodium Channel blockade:
They impede sodium ion access to the axon interior by occluding
the transmembrane sodium channels thus delaying the process of
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depolarization and axon remains polarized. It is a nondepolarization
blockade.
Pharmacodynamics:
It has got a longer duration of action but a slower onset.
Cardio vascular system:
It depresses myocardial automaticity (Spontaneous Phase IV
depolarization) and reduce the duration of the refractory period.
Myocardial contractility and conduction velocity are also depressed at
high concentrations. It causes some degree of arteriolar vasodilatation.
The ensuing combination of bradycardia, heart block, and hypotension
may culminate in cardiac arrest.
Respiratory System:
It relaxes bronchial smooth muscle. Apnea can results from
phrenic and intercostal nerve paralysis or depression of the medullary
respiratory center following direct exposure to drug.
Toxicity:
Toxicity is related to plasma level of unbound drug and more
likely due to an inadvertent intravenous injection. Systemic toxicity
reactions primarily involve central nervous system and cardio vascular
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system. The blood level required to produce central nervous system
toxicity is less than that required to produce circulatory collapse.
Central Nervous System Toxicity:
Early symptoms are circumoral numbness, tongue paresthesia,
and dizziness. Sensory complaints include tinnitus and blurred vision.
Excitatory signs (eg, restlessness, agitation, nervousness, paranoia) often
precede central nervous system depression (eg, slurred speech,
drowsiness, unconsciousness). Muscle twitching heralds the onset of
tonic clonic seizures.
Respiratory arrest often follows. The excitatory reactions are a
result of selective blockade of inhibitory pathways.
Cardiovascular System Toxicity:
The rate of depolarization in fast conducting tissue of purkinje
fibres and ventricular muscle is decreased. The rate of recovery of
bupivacaine induced block is slower than that of lignocaine.
Extremely high concentration of the drug causes sinus
bradycardia, hypotension, atrioventricular heart block, idioventricular
rhythms, and life threatening arrhythmias such as ventricular
tachycardia, ventricular fibrillation and cardiac arrest.
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aromatic  residue  on  the  other  side  and  are  joined  through  an  amide
linkage.
MECHANISM OF ACTION:
Local anaesthetics block the nerve conduction by decreasing the
entry of sodium ions during upstroke of action potential. As the
concentration of local anaesthetic is increased the rate of rise of action
potential and maximum depolarization decreases causing slowing of
conduction. Finally local depolarization fails to reach the threshold
potential and conduction block ensues. The local anesthetics interact
with a receptor situated within the voltage sensitive sodium channel and
raise the threshold of channel opening.
Sodium channel has an activation gate(A) near its extracellular
mouth and an inactivation gate(I) at the intracellular mouth. In the
resting state, the activation gate is closed. Threshold depolarization of
the membrane opens the activation gate allowing sodium ions to flow in
along the concentration gradient. Within a few milliseconds inactivation
gate closes and ion flow ceases.
The local anaesthetic recepter is located within the channel in its
intracellular half. Local anaesthetic traverses the membrane in its
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PHARMACOLOGY OF DEXAMETHASONE
Dexamethasone is a very potent and highly selective
glucocorticoid. It is a long acting drug.
PHARMACOLOGICAL ACTIONS
1. Carbohydrate and protein metabolism
Glucocorticoids promote glycogen deposition in the liver by
inducing hepatic glycogen synthetase and promoting glyconeogenesis. It
inhibits glucose utilisation in peripheral tissues. This along with
increased glucose release causes insulin resistance and a diabetes like
state. It causes protein breakdown and amino acid mobilization from
peripheral tissues, responsible for side effects like muscle wasting. The
amino acids are funneled into the liver and used for glyconeogensis.
Excess urea is produced and these cause negative nitrogen balance.
Fat metabolism
This action is primary permissive in nature. It promotes lipolysis
due to glucagon, growth hormone, adrenaline and thyroxine. Cyclic
adenosine mono phosphate (CAMP) induced breakdown of triglycerides
are enhanced.
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Fat areas in various sites respond differently and redistribution of
fat occurs. More fat is deposited in the face, neck, shoulder – (moon
face, fish mouth and buffalo hump), and there is loss of subcutaneous fat
over the extremities. The explanation to this is because the peripheral
adipocytes are less sensitive to insulin, and corticosteroid enhanced
lipolytic action of adrenaline and growth hormone predominates.
Calcium metabolism
It inhibits the intestinal absorption of calcium and increase renal
excretion of calcium. There is also loss of calcium from bone indirectly
due to loss of osteoid in chronic use. Spongy bones (vertebra, ribs) are
more sensitive.
Water excretion
Effect on water excretion is independent of action on sodium
transport, in maintaining GFR. In adrenal insufficiency the capacity to
excrete a water load is considerably reduced. Glucocorticoid enhances
the secretory capacity of renal tubules.
Cardiovascular system
Glucocorticoids restrict capillary permeability and maintain tone
of arteries and myocardial contractility. It has permissive effect on
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pressor action of adrenaline and angiotensin. They also play a role in
development of hypertension and should be cautiously used in
hypertensives.
Skeletal muscles
Optimal level of corticosteroids are needed for normal muscle
function. Weakness may occur in both hypo and hypercortism but the
effects may be different.
Hypocortism– weakness due to hypodynamic circulation
Hypercortism– excess glucocorticoid action? muscle wasting?
myopathy? weakness.
Central nervous system
Mild euphoria is common with pharmacological doses of
glucocorticoids. This is due to a direct effect on brain, independent of
relief of disease symptoms, sometimes progresses to cause increased
motor activity, insomnia, anxiety or depression. It also maintains the
level of sensory perception and normal level of excitability of neurons.
High doses, lower seizure threshold in epileptics.
35
Stomach
Secretion of gastric acid and pepsin is increased and may
aggravate peptic ulcer.
Lymphoid tissue and blood cells
Glucocorticoid drive can raise the rate of destruction of lymphoid
cells (T cells are more sensitive than B cells). However a marked lytic
response is shown by malignant lymphatic cells – usually in
lymphomas. Corticosteroid increases the number of RBCs, platelets and
neutrophils in the circulation. They decrease lymphocytes, basophils and
eosinophils. These are due to sequestration of cells. The count becomes
normal in 24 hrs.
Inflammatory responses
Irrespective of type of injury or insult, the attending inflammatory
response is suppressed by glucocorticords. This is the basis of most of
their clinical uses. It lowers all stages of inflammation. The action are
direct and even local application is possible.
The cardinal signs of inflammation such as redness, heat, swelling
and pain are suppressed. Corticosteroids are only palliative, the
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underlying disease processes continues while manifestations are
dampened.
Immunological and allergic response
They cause greater suppression of cell mediated immunity in
which T cells are primarily involved example: delayed hypersensitivity
and graft rejection. It decreases the release of interleukin-1 and
interleukin -2.
Pharmacokinetics
Dexamethasone is a water soluble ester, in the form of
dexamethasone sodium phosphate. It has an oral, intramuscular or
intravenous preparation. It acts rapidly and attain high concentration in
tissue fluids. Dexamethasone is mainly metabolized in the liver by
hepatic microsomal enzymes. The t 1/2 of dexamethasone in greater
than 36 hrs, its action starts within 30 minute of injection and action
persists even after the drug disappears from the circulation.
Drug interaction
Phenobarbitone and phenytoin induce metabolism of
dexamethasone to decrease its therapeutic effect
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USES
1. Arthritis: Used in rheumatoid arthritis in conjunction with
NSAIDs, arthritis in rheumatic fever and in gouty arthritis.
2. Collagen diseases: In disease like systemic lupus erythematosus,
polyarteritis nodosa, dermatomyositis, this drug may be life
saving.
3. Severe allergic reactions: Used in anaphylaxis for short periods,
in angioneurotic edema, urticaria, serum sickness.
4. Autoimmune diseases: Autoimmune hemolytic anemia,
thrombocytopenia, active chronic hepatitis respond to
corticosteroids.
5. Bronchial asthma: Used intravenously in status asthmaticus.
6. As  an  adjunct  to  drug  in  nausea  and  vomiting: As it prevent
the  release of inflammatory mediators and prostoglandins, they
modulate neuronal activity and have a membrane stabilising
action. It has a minimal action in nausea and vomiting. It
increases the efficacy of the drug which is co-administered.
7. Eye disease: Allergic conjuctivitis, iridocyclitis, keratitis
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8. Intestinal disease: In diseases like crohns, ulcerative colitis,
celiac disease with remissions and exacerbations.
9. Cerebral edema: In cerebral edema due to meningitis and
tumours. Dexamethasone is preferred because, it does not have
sodium retaining capacity. Large doses given in spinal injury can
reduce neurological sequalae.
10. Malignancies: As a component of chemotherapy, in ALL,
Hodgkin’s and other lymphomas.
11. In organ transplantations and skin allograft: To prevent
rejection.
12. To test adrenal –Pituitary axis function.
Contraindications for chronic use
These are only relative contraindications since, the steroid
dexamethasone is a life saving drug, they are, peptic ulcer, diabetes
mellitus, hypertension, viral and fungal infections, tuberculosis and
other infections, osteoporosis, herpes simplex keratitis, psychosis,
epilepsy, congestive heart failure, renal failure.
REVIEW OF
LITERATURE
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REVIEW OF LITERATURE
1. Yadav RK, SahBP, KumarP, SinghSN(46), compared
effectiveness of addition of dexamethasone vs neostigmine to
lignocaine ,adrenaline mixture for brachial plexus block in providing
perioperative analgesia. 90 patients were randomized in 3 groups . group
A ( lignocaine 1.5% with adrenaline 24 ml) group B (lignocaine 1.5%
with adrenaline  + 500mic gm neostigmine) and group C (lignocaine
1.5% with adrenaline +4mg dexamethasone). Mean onset of analgesia
4.6 min,4.4min,3.8 min in group A,B and C respectively and the mean
onset of motor blockade were 7.7 min,7min,6min in group A,B, and C
respectively. similarly mean complete sensory block were 10.6mins,
10.4 mins, 8.9mins and mean complete motor blockade were 17.3mins,
17.2mins and 14.7mins respectively in group A, group B, and group C.
Duration of analgesia was mean 176.5min, 225.7min and 454.2mins in
group A, group B and group C respectively. They concluded that onset
of sensory and motor block is faster and the duration of analgesia is
longer in dexamethasone group and also need less number of rescue
analgesic requirement.
2. Shrestha BR, Maharjan SK, Tabedar S(34), compared the
analgesic efficacy of local anesthetic with and without dexamethasone
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in supraclavicular brachial plexus block. 40 patients undergoing upper
limb surgeries were randomly selected and divided into 2 groups of 20
each. Group A received mixture of 2% lidocaine with 1:200000
adrenaline and bupivacaine 0.5% for a total volume of 40 to 50 ml.
group B received local anesthetic mixture with dexamethasone 4 to 8
mg. The onset of action and duration of analgesia in the two groups
were compared and any complication of the procedure were noted.
Onset of action was 18.15 min in group A and 14.5 min in group B.
duration of action in group A was mean 3.16 hrs ,in group B mean 12.75
hrs  They  concluded  that  the  onset  of  action  was  faster  and  duration  of
analgesia is prolonged in the dexamethasone group than the other group
and there were no complications.
3. Ali movafegh, Mehran razazian, Alipasha meysamie(27) studied
the analgesic efficacy of dexamethasone with lidocaine in axillary
brachial plexus blockade. 60 patients scheduled for upper limb hand and
fore arm surgeries under axillary brachial plexus block were randomly
allocated to receive either 34 ml lidocaine 1.5% with 2ml of normal
saline .(30 patients group A) or 34 ml lidocaine 1.5% with 2ml of
dexamethasone.(30 patients group B) . The duration of sensory blockade
in group A is mean 98 min and in group B 242 min. The duration of
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motor blockade in group A is mean 130min and group B is mean
310min. They concluded that the addition of dexamethasone to lidocaine
1.5%solution in axillary brachial plexus block prolongs the duration of
sensory and motor blockade.
4. Simon J. Parrington, Dermot O’ Donnell, Vincent W.S. Chan,
Rajiv subramanyam and Richard brull(36) analysed the efficacy of
dexamethasone added to mepivacaine in supraclavicular brachial plexus
block in providing post operative analgesia.45 adult patients undergoing
elective upper limb surgeries were randomized to receive either 30ml
mepivacaine 1.5% plus dexamethasone or 30ml mepivacaine 1.5% plus
2ml normal saline. Mean duration of analgesia was significantly
prolonged in dexa group (332mins) than normal saline group (228mins).
The  onset  of  action  of  sensory  and  motor  block  was  similar  in  both
groups. Complications were minor and transient and did not differ
between both groups at 2weeks post operatively. They concluded that
addition of 8mg dexamethasone to 1.5% 30 ml mepivacaine prolongs
the duration of  analgesia,  but  does not  reduce the onset  of  sensory and
motor blockade after ultrasound guided brachial plexus block compared
with mepivacaine alone.
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5. Shrestha BR, Maharjan SK, Shrestha S, Gautam B, Thapa C,
Thapa  PB,  Joshi  MR(35) compared the efficacy of tramadol and
dexamethasone as an adjuvant to bupivacaine in supraclavicular brachial
plexus block. 60 patients were randomly divided into 2groups, group A
received 0.5% bupivacaine 2ml/kg with tramadol 2mg/kg and group B
received 0.5% bupivacaine with dexamethasone 8mg.Mean onset of
motor blockade in group A is 12.90mins and in group B is
13.43mins.The mean onset of sensory blockade is 18.47mins in group A
and 16.76mins in group B. The duration of post operative analgesia was
recorded in both groups using pain VAS score which was determined by
maximum VAS score of 8 to 10 and when patient demands additional
analgesics. The mean duration of post operative analgesia in
dexamethasone group was 1028 minutes while in tramadol group it was
453.17 minutes. They concluded that dexamethasone with local
anesthetic shortens the onset of analgesia and prolongs postoperative
analgesia significantly than tramadol.
6. Franco CD, Vieira ZE (2000) did a study on Subclavian
Perivascular Block and its success using a nerve stimulator. They
concluded that the Subclavian perivascular technique consistently
provides an effective block for surgery on the upper extremity. At the
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site of injection the plexus is reduced to its smallest components and the
sheath is reduced to its smallest volume which explains in greater part
the success obtained with this block.
7. Brown DL (1993) did a study on brachial plexus anaesthesia and
analysed the various sites at which the plexus can be blocked. They
studied the supraclavicular, interscalene, infraclavicular and axillary
approaches. They concluded that the supraclavicular block produces
anaesthesia of the entire upper extremity in the most consistent and
efficient manner than any other brachial plexus block technique.
8. Lanz.E, Theiss D, Jankovic D (1983) studied  the  extent  of
blockade using various techniques of brachial plexus blocks. The extent
of sensory and motor blockade was assessed using 0.5% bupivacaine.
They concluded that the subclavian Perivascular approach of Winnie
resulted in a homogenous blockade of the nerves of the brachial plexus.
9. Winnie and Ramamoorthy (1977)(44) postulated that the trunk of
brachial plexus are arranged so that the central fibres are longest
supplying the extremities of the limb, while the shorter fibres are
arranged more peripherally as their area of supply is more proximal.
Winnie groups the fibres into two: the Peripheral Mantle bundle which
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contains the outer motor and inner sensory fibres corresponding to all
the early branches of the brachial plexus being motor: and a central core
bundle with the outer motor fibres supplying muscles of the forearm and
the inner sensory fibres carry sensation from the hand.
Thus the order of blockade is as follows:
Loss of motor power to the shoulder and upper arm; loss of
sensation in the upperarm; loss of motor power of the forearm; and loss
of sensation of the hand.
10. Lanz.E, Theiss (1979) compared the supraclavicular and the
interscalene approach of brachial plexus block. They concluded that
with the Supraclavicular block, motor as well as sensory blockade of all
the  nerves  of  the  brachial  plexus  occurred  with  about  the  same
frequency. Following both the techniques, blockade developed from the
proximal to distal with motor blockade preceding the sensory block.
11.  Viera  PA,  Pulai  I  ,  Tsao  GC,  Manikantan   P,  Keller  B,
Connelly B(42) analysed the efficacy of dexamethasone with bupivacaine
in ultrasound guided interscalene brachial plexus block for providing
perioperative analgesia. This prospective, randomized, double-blind
investigation was performed on 88 individuals undergoing shoulder
45
arthroscopy. Patients received interscalene brachial plexus block using
20 ml of 0.5%bupivacaine with 1: 200 000 epinephrine and clonidine 75
?g. Patients were randomly assigned to receive either dexamethasone 8
mg or 0.9% NaCl as an adjuvant to the mixture. After discharge,
patients recorded pain scores and analgesic consumption in a diary and
estimated the time at which they perceived that the sensory block from
the interscalene brachial plexus block resolved. In their study
dexamethasone prolonged median sensory (1457 vs. 833 min,
P<0.0001) and motor (1374 vs. 827 min, P < 0.0001) blockade
compared with the control. At 24 h, the dexamethasone group had lower
median verbal analogue scale scores compared with control (3.0 vs. 6.0).
They noted that the addition of dexamethasone with bupivacaine
increases the duration of analgesia in ultrasound guided interscalene
brachial plexus blockade.
12.  K. C. Cummings ,  D.  E.  Napier kowski,  I.  Parra-Sanchez,  A.
Kurz,   J.  E.  Dalton, J.  J.  Brems  and  D.  I.  Sessler(20) Effect  of
dexamethasone on the duration of interscalene nerve blocks with
ropivacaine or bupivacaine. In a double-blinded trial utilizing single-
injection interscalene block, patients were randomized to one of four
groups: (i) ropivacaine: 0.5% ropivacaine; (ii) bupivacaine: 0.5%
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bupivacaine; (iii) ropivacaine and steroid: 0.5% ropivacaine mixed with
dexamethasone 8 mg; and (iv) bupivacaine and steroid: 0.5%
bupivacaine mixed with dexamethasone 8 mg. The primary outcome
was time to first analgesic request after post-anaesthesia care unit
discharge. They noticed dexamethasone significantly prolonged the
duration of analgesia of both ropivacaine[ 11.8vs 22.2 h, P<0.001] and
bupivacaine [14.8 vs 22.4P<0.001] in their study. They concluded that
the addition of dexamethasone 8mg to ropivacaine or bupivacaine
prolongs the duration of analgesia.
13. Youn-Jin Kim, Jong-In Han, Hee-Jung Baik, Guie-Yong
Lee(47) The purpose of their study is to evaluate the effect of the addition
of 5mg dexamethasone to 10 ml of 5 mg/ml levobupivacaine on
postoperative analgesic effects of ultrasound guided interscalene
brachial plexus block for arthroscopic shoulder surgery under general
anesthesia. In 45 patients scheduled for arthroscopic shoulder surgery
underwent general anesthesia, interscalene brachial plexus block was
preoperatively performed with 10 ml of 5mg/ml levobupivacaine under
the guidance of ultrasound and nerve stimulator. Patients were randomly
allocated to receive same volume of normal saline (Group I), 5 mg of
dexamethasone (Group II), or 1: 400,000 epinephrine (Group III) as an
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adjuvant to the mixture. A blind observer recorded verbal numerical
rating scale (VNRS) at 0, 1, 6, 12, 24, 48h after operation, total
analgesic consumption, sleep quality, complication, and patients`
satisfaction. All patients had successful interscalene brachial plexus
blocks and excellent analgesic effects less than 4 of VNRS up to
discharge time. VNRS in Group II at 12h and 48h was statistically much
lower  than  in  Group  I  and  III.  There  were  no  differences  in  total
analgesic consumption, sleep quality, complications, and patients`
satisfaction. They conclude that the addition of 5mg of dexamethasone
to 10 ml of 5 mg/ml levobupivacaine in intersclane brachial plexus
block showed improvement of postoperative analgesia for arthroscopic
shoulder operation without specific complication.
14.  Islam SM, Hossain MHMD, Maruf AA(17) evaluated the effect
of dexamethasone added to local anaesthetics on the onset and duration
of supraclavicular brachial plexus block. Sixty adult patients undergoing
various orthopaedic surgeries on forearm and around the elbow under
supraclavicular brachial plexus block were selected and divided into 2
groups of 30 each. In group-A patients received 35 ml of mixture of
lignocaine 2%, bupivacaine 0.5% while in group-B patients received the
same amount of local anaesthetics with dexamethasone (8 mg). The
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onset of sensory and motor block and duration of analgesia in two
groups were compared and development of complications were
observed. They found the two groups were comparable indemographic
data. The mean onset time of sensory block was 11.64±2.19 minutes in
group A and 9.89±1.97 minutes in group B and difference was
statistically significant (p<0.05). Onset of motor block was 13.32±0.98
minutes in group A and 11.09±1.28minutes in group B and difference
was statistically significant (p<0.05). There was markedly prolonged
duration of analgesia in group-B, 11.87± 0.53 hours compared to group-
A, 3.43±0.49 hours. The result was statistically highly significant
(p<0.001).They concluded that the addition of dexamethasone as an
adjuvant to local anaesthetics in brachial plexus block results in
significantly early onset and markedly prolonged duration of analgesia
without any unwanted effects.
15. Golwala M, Swadia V, Dhimar A, Sridhar N(14) studied the
effect of dexamethasone as an adjuvant to local anesthetics in
supraclavicular brachial plexus block. They concluded that the addition
of dexamethasone with local anesthetic prolongs the duration of
analgesia. They also found that dexamethasone increases the intensity of
motor and sensory blockade.
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16. Kopecz DJ, Lacouture PG, WuD, et al(22) studied the dose
response and effects of dexamethasone on bupivacaine microcapsules
for intercostal blockade in human volunteers and they concluded that
dexamethasone microcapsules are well tolerated and inclusion of
dexamethasone increased the duration of intercostal block to atleast 96
hours .
17.  Ang ET,  Gold  farb  G,  Kohn S  et  al(3) analysed the efficacy of
dexamethasone given in epidural for post operative analgesia. They
found that addition of dexamethasone with local anesthetics prolongs
the post operative analgesia duration.
MATERIALS
AND
METHODS
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MATERIALS AND METHODS
This study was a prospective randomized comparative study.
After receiving the institutional ethical committee approval and
informed consent from the patients they were randomly allocated into
two groups.
A total number of 60 adult patients of both sexes in the age group
of 20 to 60 years belonging to ASA I /II category who were posted for
various type of  upper limb surgeries in the department of orthopaedics
at Government Rajiv Gandhi hospital formed the study group.
Groups :
Group A : 30 patients received 15 ml 2% lignocaine with
adrenaline  + 15 ml 0.5% bupivacaine with 2 ml of 0.9% normal saline.
Group B : 30 patients received 15 ml 2% lignocaine with
adrenaline  + 15 ml 0.5% bupivacaine with 8 mg dexamethasone.
INCLUSION CRITERIA :
ASA physical status  I / II
Age 20 to 60 years.
Patients undergoing upper limb surgery who have given informed
consent.
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EXCLUSION CRITERIA :
ASA physical status III / IV
Patients with coagulation abnormalities.
History of allergy to local anesthetics
Patchy or inadequate analgesia
Diabetes
Acid peptic disease
Patient refusal
Patient requiring conversion to GA
Patient not fitting into inclusion criteria
EQUIPMENTS :
Sterile tray
Sterile towel
Sterile swabs
Sponge holding forceps
Povidone iodine solution
10 ml syringe
2ml syringe with 24 G needle
0.5% bupivacaine vial
Freshly prepared 2% lignocaine with adrenaline 1:200000 vial
Dexamethasone 8mg
25 G spinal needle
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INTRAOPERATIVE AND POSTOPERATIVE MONITORING :
(1) Heart rate, (2) SPO2, (3) NIBP, (4) ECG
Initially the pre procedure parameters were recorded.ie , heart
rate, systolic BP, diastolic BP, MAP, SPO2, ECG. These were taken as
baseline values before giving the block. All through the study these
parameters were monitored continuously except the NIBP which was
recorded intermittently. Postoperatively they were monitored upto
regression of motor and sensory blockade. Patients were observed
vigilantly for the development of complications.
SUBCLAVIAN PERIVASCULAR TECHNIQUE:
1. IV line was started for all the patients with 18 G I.V cannula after
connecting monitors to the patient.
2. Patient was positioned on the table and proper illumination was
done at the site of block.
3. For continuous neurological evaluation no sedative drugs were
administered preoperatively.
4. Patient placed in supine position with head turned to the side
opposite to the side that is to be injected.
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5. The arms are at the patient’s side with the hands pointing towards
the knee.
6. A rolled towel is placed lengthwise between the shoulders along
the spine to give the best exposure to the blocking area.
7. The area is aseptically prepared and draped.
8. The anesthesiologist stands at the head end of the table.
9. The patient is asked to lift the head slightly to bring the clavicular
head of sternomastoid into prominence.
10. The index finger is placed lateral to the muscle and the patient is
asked to relax. Roll the index finger laterally across the belly of
the muscle until the inter scalene groove is palpated.
11. The finger is then moved inferiorly down the groove until the
pulse of subclavian artery is palpated.
12. A  skin  wheal  is  raised  at  a  point  about  2  to  2.5  cm  above  the
midpoint of clavicle with 1 ml of 2% lignocaine by a 24 G needle.
13. The palpation of subclavian artery against the palpating finger is a
guide to supraclavicular block.
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14. A spinal needle is held between the thumb and index finger,
inserted at the point where we raised local anesthetic wheal.
15. The needle is directed towards the ipsilateral nipple, posterolateral
to the subclavian artery.
16. Within 2cm a pop off is felt or parasthesia may be elucited, it
indicates the needle is inside the sheath and closer to the nerve
bundle. Then the local anesthetic solution is given in 5ml
increments with frequent aspiration to prevent intravascular
injection.
17. Intercostobrachial nerve and medial cutaneous nerve are blocked
separately at the axilla anterior to the axillary artery by
subcutaneous infiltration of local anesthetic to ensure complete
anesthesia of the upper extremity.
18. The needle should not be advanced beyond 2.5cm to avoid the
risk of complications. A cough by the patient is a warning that the
pleura is being irritated by the needle.
19. After injecting the local anesthetic the block is tested for both
sensory and motor blockade and is compared with the
contralateral limb.
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EVALUATION OF MOTOR BLOCKADE:
Motor block is evaluated by thumb abduction (radial nerve),
thumb adduction (ulnar nerve), thumb opposition (median nerve) and
flexion  of  the  elbow  in  supination  and  pronation  of  the  fore  arm
(musculocutaneous nerve) for every one minute.
EVALUATION OF SENSORY BLOCKADE:
Sensory blockade is evaluated by pinprick in the area of the above
four nerves for every 1 minute. The Hollmen’s scale is used in the study
for assessing both sensory and motor blockade.
MOTOR BLOCKADE:
0 - normal muscle power
+ -  slight depression of muscle power as compared with
preanesthetic power
++ - very weak muscular action persisting in muscle.
+++ - complete blockade with absent muscle power . (onset
of motor  blockade means 3+)
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SENSORY BLOCKADE:
0 - normal sensation for pin prick.
+ - pin prick felt as sharp pointed but weaker Compared
with the same area in other limb
++ - pin prick felt as touch with blunt object
+++ - no  perception  of  pin  prick.  (onset  of  sensory
blockade means 3+)
Evaluation was carried for every minute after completion of the
injection  and  the  time  of  onset  was  noted  for  both  sensory  and  motor
blockade. Only patients with complete motor and sensory blockade were
included in the study. Once block was complete surgery was allowed to
proceed.
Duration of sensory blockade was considered as the time interval
between the complete sensory blockade and the onset of regression of
sensory blockade – first pain to pin prick.(VAS 3)
Duration of motor blockade was considered as the time interval
between the complete motor blockade and onset of regression of motor
blockade.
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In the postoperative period the regression of motor and sensory
blockade was tested for every 30 minutes.
MONITORING :
Monitoring during anesthesia focuses on systemic toxicity of
local anesthetic, complications of block like pneumothorax and horners
syndrome. Parameters like heart rate, systolic BP, diastolc BP, MAP,
SPO2, ECG are recorded preblock and monitored throughout the
surgery and in the postoperative period upto the onset of regression of
motor and sensory blockade. In the postoperative period pain was
assessed using a numerical rating pain score scale (visual analogue
scale) where 0 represents no pain,10 represents the worst possible pain.
OBSERVATIONS
AND
RESULTS
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OBSERVATION AND RESULTS
This randomized, prospective, single blinded, case controlled
study analyses the effectiveness of dexamethasone as an adjuvant to
local anesthetic mixture in providing postoperative analgesia in
supraclavicular brachial plexus block.
Results are expressed as mean and standard deviation. All
statistical analyses were carried out using SPSS for Windows version
15.0. The t-test was used for comparison of quantitative variants.
Qualitative variants were compared using the chi-square test. A ‘P
value’ of less than 0.05 was considered statistically significant.
Table 1. Demographic profile: Age
Group Number Mean SD P value
A 30 37.73 13.385 0.386
N.SB 30 34.93 11.362
The mean age of group A is 37.73 and group B is 34.93, the p
value is 0.386, it is not statistically significant. Both groups are
comparable in terms of age.
59
Table 2. Demographic profile: Sex
Group
Male Female
P value
No % No %
A 25 83.3 5 16.7 0.739
N.SB 24 80.0 6 20.0
The percentage of male patients in group A is 83.3 and in group B
is 80.0, the percentage of female patients in group A is 16.7 and in
group B is 20.0, p value is 0.739, it is not statistically significant. Both
groups are comparable in terms of sex.
Table 3. Demographic profile: BMI
Group No Mean SD P value
A 30 24.97 1.502 0.288
N.SB 30 24.60 1.214
The mean BMI of group A is 24.97 and group B is 24.60, the p
value is 0.288, it is not statistically significant. Both groups are
comparable in terms of BMI.
Table  4. Demographic profile ASA PS:
Group
ASA I ASA II
P value
No % No %
A 25 83.3 5 16.7 0.718
N.SB 26 86.7 4 13.3
In group A 25 patients were ASA I and 5 were ASA II patients. In
group B 26 patients were in ASA I and 4 were ASA II patients. The data
is statistically not significant (p>0.05) and this both groups are
comparable in terms of ASA PS Status
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Table 5. Onset of motor blockade:
Group No Mean SD P value
A 30 15.13 0.860 <0.005
SIGB 30 13.33 0.884
The mean onset of  motor blockade in group A is 15.13 minutes,
in group B is 13.33 minutes. Statistical analysis reveal p value  <0.005,
it is statistically significant.
Table 6. Onset of sensory blockade:
Group No Mean SD P value
A 30 19.30 0.915 <0.005
SIGB 30 16.43 0.774
The mean onset of sensory blockade in group A is 19.30, and in
group B is 16.43 minutes. Statistical analysis reveal p value < 0.005,
which is statistically significant.
Table 7. Quality of anesthesia:
Group
                 Quality
P value1 2 3
No % No % No %
Group A _  4 13.3 26 86.7 0.161
N.SGroup B _  1 3.3 29 96.7
In group A the quality of anesthesia is 3 for 26 patients, 2 for 4
patients and in group B it is 3 for 29 patients and 2 for 1 patient.
Statistical analysis shows the p value is 0.161, which is not significant.
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Table 8. Duration of surgery:
Group No Mean SD P value
A 30 152.47 11.530 0.690
N.SB 30 153.40 15.843
The mean duration of surgery in group A is 152.47, and in group
B is 153.40. statistical analysis show the p value is 0.690. The p value is
not statistically significant.
Table 9. Duration of motor blockade:
Group No Mean SD P value
A 30 207.67 16.219 < 0.005
SIGB 30 374.93 13.829
The mean duration of motor blockade in group A is 207.67
minutes, in group B is 374.93 minutes. Statistical analysis show the p
value < 0.005, which is statistically significant.
Table 10. Duration of sensory blockade:
Group No Mean SD P value
A 30 318.77 20.997 <0.005
SIGB 30 642.33 30.250
The mean duration of sensory blockade in group A is 318.77
minutes, in group B is 642.33 minutes. Statistical analysis show the p
value is <0.005, which is statistically significant.
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Table 11. Heart rate:
Group No Mean SD P value
Pre block
A 30 79.37 6.615
0.599 NS
B 30 78.53 4.819
1 min
A 30 81.67 6.166
0.504 NS
B 30 82.70 5.742
5 min
A 30 81.40 6.360
0.561 NS
B 30 82.40 6.881
10 min
A 30 79.40 6.621
0.386 NS
B 30 80.87 6.383
15 min
A 30 76.97 6.425
0.176 NS
B 30 79.07 5.407
30 min
A 30 75.23 5.728
0.195 NS
B 30 77.13 5.494
45 min
A 30 74.63 5.762
0.205 NS
B 30 76.43 5.090
End
A 30 75.27 4.820
0.935 NS
B 30 75.37 4.694
The heart rate is measured pre block and 1 min, 5mins,
10mins,15mins, 30mins, 45mins after the block and at the end of the
surgery. Statistical analysis using student t test shows the p value of
0.599, 0.504, 0.561, 0.386, 0.176, 0.195, 0.205, and 0.935 respectively,
which are not significant.
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Tables 12. Systolic blood pressure:
Group No Mean SD P value
Pre block
A 30 126.67 7.232
0.435 NS
B 30 125.20 7.208
1 min
A 30 130.07 8.128
0.480 NS
B 30 128.70 6.691
5 min
A 30 131.40 6.688
0.694 NS
B 30 130.77 5.685
10 min
A 30 128.77 6.426
0.475 NS
B 30 127.60 6.145
15 min
A 30 125.23 5.876
0.313 NS
B 30 123.73 5.539
30 min
A 30 122.67 6.315
0.367 NS
B 30 121.30 5.279
45 min
A 30 120.63 6.014
0.561 NS
B 30 119.83 4.480
End
A 30 120.00 4.756
0.895 NS
B 30 119.83 5.004
The systolic blood pressure is measured during pre block, 1min,
5mins,  10mins, 15mins, 30mins, 45mins after the block and at the end
of the surgery. Statistical analysis using student t test shows the p value
of 0.435, 0.480, 0.694, 0.475, 0.313, 0.367, 0.561, and 0.895
respectively, which is not significant.
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Table 13. Diastolic blood pressure:
Group No Mean SD P value
Pre block
A 30 77.57 6.021
0.769 NS
B 30 77.13 5.322
1 min
A 30 80.33 6.326
0.588 NS
B 30 79.47 5.998
5 min
A 30 80.77 6.532
0.396 NS
B 30 79.30 6.742
10 min
A 30 77.63 6.693
0.405 NS
B 30 76.23 6.229
15 min
A 30 74.47 6.511
0.160 NS
B 30 72.33 4.999
30 min
A 30 71.73 5.836
0.258 NS
B 30 70.20 4.483
45 min
A 30 69.67 5.416
0.849 NS
B 30 69.43 3.945
End
A 30 69.03 4.767
0.699 NS
B 30 69.47 3.821
Table 14. Complication: Nausea:
Group
Nausea
P valueYES NO
No % No %
A 3 10 27 90 0.301 NS
B 1 3.3 29 96.7
In group A 3 patients complaints of nausea, 27 patients are nausea
free, in group B 1 patient complaints of nausea, and 29 patients are free
of nausea. Statistical analysis shows the p value of 0.301, which is
statistically not significant.
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Table 15. Mean Arterial Pressure:
Group No Mean SD P value
Pre block
A 30 93.87 6.280
0.633 NS
B 30 93.13 5.529
1 min
A 30 96.88 6.733
0.588 NS
B 30 95.84 5.851
5min
A 30 97.41 6.150
0.533 NS
B 30 96.42 6.143
10 min
A 30 94.51 6.452
0.306 NS
B 30 92.87 5.802
15 min
A 30 91.33 6.051
0.164 NS
B 30 89.33 4.876
30 min
A 30 88.68 5.760
0.278 NS
B 30 87.21 4.577
45 min
A 30 86.62 5.402
0.736 NS
B 30 86.21 3.913
End
A 30 85.99 4.543
0.891 NS
B 30 86.16 4.621
The diastolic blood pressure and mean arterial pressure are
measured during pre block, 1min, 5mins, 10mins, 15mins, 30mins,
45mins, after the block, and at the end of the surgery. The p values are
calculated using student t test, which are shown on the table 13 and table
14. The p values are statistically not significant.
1. AGE
37.73
34.93
33
34
35
36
37
38
A B
AGE
Mean
2. SEX
25 24
5 6
0
5
10
15
20
25
male female
SEX
A B
3. BMI
24.97
24.6
24.4
24.6
24.8
25
A B
BMI
Mean
4. ASA STATUS:
25
5
26
4
0
5
10
15
20
25
30
A B
ASA STATUS
ASA I ASA II
5. MOTOR BLOCK ONSET:
15.13
13.33
12
13
14
15
16
A B
MOTOR BLOCK ONSET
Mean
6. SENSORY BLOCK ONSET:
19.3
16.43
14
15
16
17
18
19
20
A B
SENSORY BLOCK ONSET
Mean
7. QUALITY OF ANESTHESIA:
0 0
4
1
26
29
0
5
10
15
20
25
30
ONE TWO THREE
QUALITY OF ANESTHESIA
A B
8.  DURATION OF SURGERY:
152.47
153.4
152
152.5
153
153.5
A B
DURATION OF SURGERY
MEAN
9. DURATION OF MOTOR BLOCKADE:
207.67
374.93
0
100
200
300
400
A B
DURATION OF MOTOR BLOCKADE
MEAN
10. DURATION OF SENSORY BLOCKADE:
318.77
642.63
0
200
400
600
800
A B
DURATION OF SENSORY BLOCK
MEAN
11. COMPLICATIONS:
3 1
27 29
0
5
10
15
20
25
30
YES NO
COMPLICATION: NAUSEA
A B
12. HEART RATE:
70
72
74
76
78
80
82
84
A B
HEART RATE
pre block 1 min 5 min 10 min 15 min 30 min 45 min end
13. SYSTOLIC BLOOD PRESSURE:
110
115
120
125
130
135
pre
block
1 min 5 min 10 min 15 min 30 min 45 min end
SYSTOLIC BP
A B
14. DIASTOLIC BLOOD PRESSURE:
60
65
70
75
80
85
pre
block
1 min 5 min 10 min 15 min 30 min 45 min end
DIASTOLIC BP
A B
15. MEAN ARTERIAL PRESSURE:
80
85
90
95
100
pre
block
1 min 5 min 10 min 15 min 30 min 45 min end
MEAN ARTERIAL PRESSURE
A B
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DISCUSSION
Brachial plexus block is an easy and relatively safe procedure for
upper limb surgeries. A combination of lignocaine and bupivacaine
provided better operating conditions but the duration of analgesia is
rarely maintained for more than 4-6 hours. Addition of steroid to local
anaesthetics effectively and significantly prolongs the duration of
analgesia as well as producing earlier onset of action. Steroids are very
potent anti-inflammatory and immunosuppressive agents. Perineural
injection of steroid is reported to influence post operative analgesia.
Epidural steroids were used for treatment of back pain and sciatica.
Various steroids has been used for this purpose, but
dexamethasone a 9 alpha derivative synthetic glucocorticoid is preferred
because of its highly potent anti-inflammatory property, about25-30
times as potent as hydrocortisone and without any mineralocorticoid
activity. Thus was found to be safer and devoid of potential side effects.
Pre-operative administration of dexamethasone by oral and intravenous
routes has been shown to reduce overall pain scores and analgesic
requirements in the postoperative period without any adverse effects in
various dental and general surgical procedures.  (Baxendale  et  al(5),
Miralles et al(26), Elhakim M et al(12)).
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Dexamethasone is also known to reduce post-operative nausea
and vomiting. The possible mechanism ofanalgesic and antiemetic
actions are due to anti-inflammatory property of Dexamethasone.
(Ahlgren et al(1), Bisgaard T et al(7)).
It  has  been  also  observed  that  addition  of  small  amount  of
dexamethasone to local anesthetics prolonged the duration of analgesia
after subcutaneous, intercostal block, intra articular, and epidurally.
(Holt et al(16), Kopacz et al(22), Stein et al(38), Ang et al(3)).
1. In our study mean age in group A is 37.73 and in group B it is
34.93 both groups are comparable in terms of age.
2. Mean value of BMI in group A is 24.97, and in group B is 24.60 p
value is not significant, both groups are comparable in terms of
BMI.
3. Number of male patients in group A is 25 and in group B is 24,
number of female patients in group A is 5 and in group b is 6.
Both groups are comparable in terms of sex.
4. Number of patients with ASA  I  in group A is 25 and in group B
is 26 number of patients with ASA II in group A is 5 and in group
B is 4. Both groups are comparable in terms of ASA PS status.
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5. Quality of anesthesia, in group A surgeons graded 26 cases as
grade3 and 4 cases as grade 2. In group B surgeons graded 29
cases as grade 3 and 1 case as grade 2. This finding is not
statistically significant.
6. Duration of surgery, in both groups are comparable and not
statistically significant.
7. Hemodynamic parameters like heart rate, systolic BP, diastolic
BP, mean BP are comparable in both groups, are statistically
insignificant.
8. Onset of motor blockade and sensory blockade:
In our study onset of motor blockade and onset of sensory
blockade occurs earlier in dexamethasone group. Our finding is
comparable with the study conducted by Shrestha B.R et al(35) in
40 patients. They found that complete sensory blockade in
dexamethasone group occurs in mean 16.76mins, and complete
motor blockade occurs in mean 12.90 mins. The early onset of
action might be due to synergistic action of dexamethasone with
local anaesthetics on blockage of nerve fibres.
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In our study motor blockade occurs earlier than sensory blockade,
this finding is comparable with the study conducted by Winnie in
1977(44), he described the outer motor fibers are blocked earlier
than the sensory fibers which are situated deeper in the plexus at
the level of trunk and division. This finding is also comparable
with the study conducted by Shrestha B.R et al(34).
9. Duration of motor and sensory blockade:
In our study regression of motor blockade occurs earlier than
sensory regression, this finding is comparable with the study
conducted by De Jong et al(9).
The duration of pain relief (postoperative analgesia) was
markedly prolonged (mean 642.63) in dexamethasone group, while it
was only 318.77mins in control group.This results are similar to
findings of study of Yadav et al(46).
Ali movafegh et al(27) also stated that dexamethasone prolongs
the duration of analgesia in axillary block in 60 patients with lignocaine
in their study.
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Probable mechanism of  action of dexamethasone in prolonging
the sensory blockade was postulated by number of studies. Prithviraj(31)
and Johanson etal(18) found that the steroids have the nocioceptive c
fibres blocking quality.
In another study Pennington et al(29) and Attardi et al(4) found
that the steroids act  by alteration of k+ channel, there by synergistically
act with local anesthetics in nerve fibres.
In their study Ahlgren et al(1) found that the analgesic action is
mediated by anti inflammatory effects of steroids.
Steroids have vasoconstrictory action and this action is attributed
that to the analgesia prolonging action similar to the action of adrenaline
when added with local anesthetics Seidenari et al(33).
Other possibilities are action on corticosteroid receptor in brain
after being absorbed from periphery to systemic circulation (Benzon
HT(6) and  Pieretti  et  al(30)) suppression of ectopic neuronal discharge
(Devor et al(10)).
In one study after approximately 2000 intrathecal injections of
dexamethasone 8mg in 200 patients for treatment of posttramatic visual
disturbance Sugita et al(39) found no neurological complications.
SUMMARY
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SUMMARY
From this prospective, randomised, comparative, single blinded,
case control study which evaluated the effectiveness of dexamethasone
as an adjuvant to local anesthetic mixture in providing post operative
analgesia in supraclavicular brachial plexus block we found that,
1. The  demographic  profiles  like  Age,  Sex,  BMI,  ASA  status  are
comparable in both groups.
2. The onset of motor block occurs earlier in dexamethasone group
than control group.
3. The onset of sensory block occurs earlier in dexamethasone group
than control group.
4. The onset of motor block occurs earlier than sensory block in both
groups.
5. The quality of anesthesia, duration of surgery, hemodynamic
parameters, complications are comparable in both groups.
6. The duration of motor block is longer in dexamethasone group
than control group.
7. The duration of sensory block is longer in dexamethasone group
than control group.
CONCLUSION
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CONCLUSION
From our study we conclude that addition of dexamethasone 8mg
to local anesthetic mixture fastens the onset of action of motor and
sensory blockade, and prolongs the duration of motor blockade and
analgesia significantly. It may be useful in situations where epinephrine
must be used with caution i.e. hypertension and ischemic heart disease.
Further studies are required to elucidate the mechanism of action,
determine the optimal dose, and examine the safety profile of
dexamethasone before its routine use as perineural adjuant can be
advocated.
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MASTER CHART
GROUP A :
S.No. NAME AGE SEX BMI ASA MB SB
1 RAVINDRAN 47 M 25.2 I 15 19
2 ANJALI 30 F 24.05 I 17 21
3 JAYARAMAN 25 M 24.2 I 14 18
4 ARUL 26 M 25.3 I 16 20
5 SUNDARAMURTI 30 M 24.7 I 15 19
6 VIJAY 26 M 25.7 I 16 21
7 SATHYAMURTI 45 M 24.6 I 14 20
8 PRABHU 25 M 27 I 15 19
9 EDWARD JOHN 58 M 24.2 II 14 18
10 THAYAMMAL 55 F 27.19 II 16 19
11 SANTHAKUMAR 23 M 26.1 I 15 19
12 MUNUSAMI 45 M 23.5 I 14 20
13 KALIDOSS 26 M 24.9 I 15 21
14 SAMPATH 55 M 23.3 II 15 19
15 MURUGAN 39 M 24.2 I 14 18
16 GOPIKANNAN 20 M 24.3 I 14 19
17 DHANALAKSHMI 55 F 25.2 II 16 20
18 DURAIRAJ 55 M 24.1 I 16 20
19 THENDRAL 23 M 25.4 I 16 19
20 JAMIM 20 M 25.3 I 15 19
21 MANIVANNAN 30 M 25.1 I 16 19
22 VASUKI 48 F 29.3 I 15 19
23 MEGARAJ 54 M 26.1 I 14 19
24 SURESH 24 M 22.5 I 14 18
25 ANNAVU 56 M 23.4 II 15 18
26 SUBRAMANI 46 M 24.6 I 15 20
27 VIJAYAN 35 M 22.3 I 16 21
28 DEVAKI 37 F 28 I 16 19
29 HARIBABU 22 M 24.8 I 15 19
30 SUBRAMANI 52 M 24.8 I 16 19
GROUP A :
S.No Q.O.A D.O.S D.O.M.B D.O.S.B Nausea P.T allergy palsy H.syn
1 3 151 221 330 No No No No No
2 2 154 229 278 No No No No No
3 3 141 188 308 No No No No No
4 3 144 199 356 No No No No No
5 3 156 236 330 No No No No No
6 2 156 204 299 No No No No No
7 3 148 193 309 No No No No No
8 3 158 203 327 Yes No No No No
9 3 147 222 316 No No No No No
10 3 157 184 337 No No No No No
11 3 157 202 321 No No No No No
12 3 130 210 306 No No No No No
13 2 152 177 283 No No No No No
14 3 156 238 340 No No No No No
15 3 162 227 344 No No No No No
16 3 159 204 314 Yes No No No No
17 3 162 217 336 No No No No No
18 3 145 215 324 No No No No No
19 3 145 189 333 No No No No No
20 3 174 209 293 No No No No No
21 3 156 199 296 No No No No No
22 3 135 210 304 No No No No No
23 2 152 207 290 No No No No No
24 3 172 178 296 No No No No No
25 3 142 212 335 No No No No No
26 3 174 205 300 No No No No No
27 3 134 209 329 No No No No No
28 3 140 236 352 yes No No No No
29 3 144 211 343 No No No No No
30 3 171 196 334 No No No No No
GROUP A: HEART RATE:
S.No PRE B 1min 5min 10min 15min 30min 45min END
1 79 85 89 86 81 77 75 74
2 87 94 93 90 84 80 76 79
3 90 86 82 74 70 67 69 75
4 84 87 83 87 85 84 82 80
5 96 84 77 74 72 68 69 72
6 75 79 77 80 84 83 84 80
7 68 69 74 72 67 65 63 66
8 76 79 84 83 80 79 84 82
9 69 68 70 70 67 68 69 67
10 74 73 77 75 74 75 73 72
11 82 80 86 82 80 76 74 77
12 75 79 84 82 80 77 75 76
13 82 86 84 80 76 74 74 72
14 72 75 77 69 67 68 68 70
15 82 84 80 84 87 83 80 79
16 86 82 87 83 80 76 74 76
17 82 84 83 85 82 80 79 77
18 69 74 67 66 64 67 66 65
19 76 79 83 82 80 76 75 77
20 76 78 74 73 70 69 71 73
21 82 87 83 84 79 76 77 80
22 87 89 91 90 86 84 83 80
23 72 75 70 67 69 67 65 68
24 79 87 86 84 80 81 80 77
25 74 80 76 73 75 77 74 71
26 77 79 83 80 76 75 76 79
27 78 85 84 80 76 77 79 80
28 86 89 90 87 86 82 83 83
29 82 87 83 80 76 75 72 74
30 84 87 85 80 76 71 70 77
GROUP A: SYSTOLIC BLOOD PRESSURE:
S.No Pre B 5 min 10 min 15 min 20 min 30 min 45 min End
1 130 136 132 124 122 118 120 124
2 128 129 137 136 130 128 126 122
3 124 128 126 120 118 118 116 119
4 118 110 116 128 120 106 104 108
5 128 136 136 130 127 124 122 120
6 119 128 128 124 118 118 120 124
7 130 136 140 142 137 132 126 118
8 124 126 130 130 127 124 120 117
9 136 139 143 145 137 132 130 124
10 134 138 132 126 120 118 117 112
11 124 120 124 124 122 123 125 126
12 128 130 132 130 127 124 122 118
13 116 120 124 130 132 136 132 127
14 134 139 137 130 130 124 126 120
15 130 132 126 124 119 116 115 112
16 132 136 130 124 122 118 116 119
17 137 139 146 142 137 132 127 122
18 134 137 132 130 127 126 125 120
19 118 120 127 122 118 117 114 114
20 116 124 127 129 125 121 124 125
21 124 126 127 121 118 124 125 126
22 126 134 137 132 124 120 116 112
23 136 139 142 133 130 130 123 120
24 114 119 124 126 127 119 126 125
25 136 139 140 137 132 130 124 120
26 130 136 130 124 120 121 114 124
27 124 128 129 127 126 118 113 119
28 118 116 126 120 124 126 119 124
29 116 124 130 127 120 117 114 121
30 136 138 132 126 121 120 118 118
GROUP A: DIASTOLIC PRESSURE:
S No Pre B 5 min 10 min 15 min 20 min 30 min 45 min End
1 81 85 82 76 70 69 70 73
2 76 76 84 82 80 74 74 70
3 72 74 73 67 64 63 62 64
4 70 70 72 75 72 64 64 65
5 73 80 84 80 78 75 71 67
6 72 77 76 72 69 67 70 72
7 84 87 90 92 89 84 80 74
8 73 78 82 81 76 72 69 66
9 87 90 94 92 89 84 74 75
10 85 86 80 74 70 69 65 63
11 77 74 76 75 71 70 72 74
12 79 84 87 83 80 75 72 67
13 70 76 79 80 81 84 83 76
14 82 85 83 80 82 79 75 72
15 76 77 74 74 70 64 64 60
16 84 87 82 77 73 70 67 70
17 89 92 95 93 84 80 75 74
18 85 86 83 81 76 74 72 70
19 73 75 76 71 69 67 64 62
20 70 72 73 75 73 70 72 77
21 74 76 75 70 70 70 77 74
22 70 77 76 72 67 66 62 60
23 84 87 90 75 72 70 65 63
24 72 74 75 73 74 70 72 72
25 85 89 91 86 81 76 72 70
26 80 84 74 69 63 65 64 70
27 75 77 74 73 72 70 64 66
28 72 70 78 72 70 70 64 67
29 73 78 82 79 73 69 65 71
30 84 87 83 80 76 72 70 67
GROUP A : MEAN ARTERIAL PRESSURE:
S No Pre B 5 min 10 min 15 min 20 min 30 min 45 min End
1 97.3 102 98.6 92 87.3 85 86.6 90
2 93.3 93.6 101.6 100 96.6 92 91.3 87.3
3 89.3 92 90.6 84.6 82 81.3 80 82.3
4 86 83.3 86.6 92.6 88 78 77.3 79.3
5 90.3 98.6 101.3 96.6 94.3 91.3 88 84.6
6 87.6 94 93.3 89.3 85.3 84 86.6 89.3
7 99.3 103.3 106.6 108.6 104 100 95.3 88.6
8 90 94 98 97.3 93 89.3 86 83
9 103.3 106.3 110.3 109.6 105 100 92.6 91.3
10 101.3 103.3 97.3 91.3 86.6 85.3 82.3 79.3
11 92.6 89.3 92 91.3 88 87.6 89.6 91.3
12 95.3 99.3 102 98.6 95.6 91.3 88.6 84
13 85.3 90.6 94 96.6 98 101.3 99.3 93
14 99.3 103 101 96.6 98 94 92 88
15 94 95.3 91.3 90.6 86.3 81.3 81 77.3
16 100 103.3 98 92.6 89.3 86 83.3 86.3
17 105 107.6 112 109.3 101.6 97.3 92.3 90
18 101.3 103 99.3 97.3 93 91.3 89.6 86.6
19 88 90 93 88 85.3 83.6 80.6 79.3
20 85.3 89.3 91 93 90.3 87 89.3 93
21 90.6 92.6 92.3 87 86 88 93 91.3
22 88.6 96 96.3 92 86 84 80 77.3
23 101.3 104.3 101.3 94.3 91.3 90 84.3 82
24 86 89 91.3 90.6 91.6 86.3 90 89.6
25 102 105.6 107.3 103 98 94 89.3 86.6
26 96.6 101.3 92.6 87.3 82 83.6 80.6 88
27 91.3 94 92.3 91 90 86 80.3 83.6
28 87.3 85.3 94 88 88 88.6 82.3 86
29 87.3 93.3 98 95 88.6 85 81.3 87.6
30 101.3 104 99.3 91.3 91 88 86 84
MASTER CHART:
GROUP B :
S.No NAME AGE SEX BMI ASA MB SB
1 CHINASAMY 56 M 24.4 II 12 15
2 MUTHUKRISHNAN 56 M 24.8 I 13 17
3 KANIAPPAN 50 M 24.6 I 13 16
4 PARTHASARATI 46 M 25.3 I 14 17
5 DANAPAL 34 M 26.3 I 15 16
6 ELAMARI 50 F 26.4 II 12 16
7 MOORTHI 25 M 23 I 14 17
8 MAHESWARI 40 F 23.9 I 13 16
9 KARTHIK 32 M 22.7 I 15 18
10 MANIVEL 33 M 23.2 I 12 16
11 PARVANDADAS 21 M 25.19 I 13 18
12 MANJULA 24 F 24.5 I 13 16
13 SELVARAJ 36 M 25.5 I 14 16
14 BACKYARAJ 28 M 24.5 I 13 16
15 ELANGO 26 M 23.7 I 14 17
16 GOPAL 35 M 24.4 I 13 16
17 KARUPASAMI 58 M 24.6 II 12 17
18 RAVISHANKAR 22 M 25 I 13 16
19 SUMITHRA 24 F 25.9 I 14 15
20 LOKESH 35 M 24.2 I 14 16
21 KRISNAMOORTI 35 M 23 I 13 16
22 SHANMUGAM 40 M 22.3 I 13 17
23 NAVEEN 22 M 26.5 I 14 18
24 JODHA 29 M 24.1 I 15 17
25 SATISH KUMAR 40 M 24.8 I 13 16
26 MALARVIZHI 48 F 25.7 II 14 17
27 VENKATESH 33 M 26.1 I 14 16
28 TAMILMANI 20 M 24.8 I 13 17
29 RAGUPATI 21 M 22.3 I 12 16
30 POORI 29 F 26.3 I 13 16
GROUP B :
SNO Q.O.A D.O.S D.O.M.B D.O.S.B Nausea P.T Allergy Palsy H.synd
1 3 174 368 652 No No No No No
2 3 182 362 612 No No No No No
3 3 163 359 653 No No No No No
4 3 152 382 646 No No No No No
5 3 138 378 665 No No No No No
6 3 128 374 698 No No No No No
7 3 129 369 633 No No No No No
8 3 169 377 603 No No No No No
9 3 163 386 640 No No No No No
10 3 151 357 702 No No No No No
11 3 173 399 685 No No No No No
12 3 156 396 671 No No No No No
13 3 161 391 660 No No No No No
14 3 155 367 641 No No No No No
15 3 168 373 637 No No No No No
16 3 151 380 644 No No No No No
17 3 138 397 658 No No No No No
18 3 148 398 612 No No No No No
19 2 160 370 597 No No No No No
20 3 172 377 605 No No No No No
21 3 153 363 647 No No No No No
22 3 145 355 635 No No No No No
23 3 149 364 599 No No No No No
24 3 166 371 596 Yes No No No No
25 3 154 394 703 No No No No No
26 3 140 390 644 No No No No No
27 3 135 375 653 No No No No No
28 3 123 363 628 No No No No No
29 3 138 353 613 No No No No No
30 3 183 360 647 No No No No No
GROUP B: HEART RATE:
S No PRE B 1min 5min 10min 15min 30min 45min End
1 72 72 73 70 67 62 68 67
2 74 73 70 67 69 70 71 73
3 69 74 72 70 73 74 72 70
4 75 79 73 74 76 72 77 71
5 80 83 82 80 76 75 72 76
6 69 72 68 70 71 73 70 67
7 77 84 87 89 84 82 80 77
8 74 87 89 90 83 80 81 77
9 80 86 83 87 80 76 79 75
10 82 89 92 87 86 80 77 76
11 84 86 89 87 83 80 82 81
12 87 92 94 89 86 82 83 84
13 79 76 72 77 74 75 73 72
14 86 82 87 86 84 83 82 81
15 82 87 86 82 80 76 74 72
16 76 79 82 80 77 75 76 78
17 69 74 77 75 72 67 66 65
18 80 87 89 86 85 87 87 83
19 79 84 86 83 85 83 80 76
20 77 82 80 81 83 82 79 78
21 82 87 85 83 80 79 77 74
22 80 83 80 79 76 73 75 76
23 82 87 86 87 84 82 83 80
24 87 89 89 86 83 82 79 78
25 77 76 79 74 75 73 70 70
26 79 86 83 82 80 81 76 75
27 80 83 80 81 79 77 80 78
28 79 89 90 77 74 72 70 75
29 80 87 86 83 85 83 80 81
30 79 86 83 84 82 78 74 75
GROUP B: SYSTOLIC BLOOD PRESSURE:
S. No PRE B 5 min 10 min 15 min 20 min 30 min 45 min End
1 132 135 139 132 130 126 130 132
2 130 132 135 130 126 124 120 118
3 134 136 137 128 122 118 116 119
4 136 132 130 124 126 119 117 120
5 118 116 124 120 118 116 112 107
6 130 128 136 132 124 122 124 120
7 126 129 134 132 127 120 118 117
8 130 136 139 132 126 122 116 115
9 116 126 123 121 117 116 119 121
10 108 112 126 122 115 114 117 119
11 126 129 126 120 119 121 123 127
12 128 132 130 125 120 116 115 118
13 112 118 136 132 124 122 118 116
14 118 134 133 126 119 117 119 124
15 124 130 125 120 118 120 124 126
16 127 130 128 126 118 116 118 121
17 136 142 144 147 136 132 130 124
18 118 126 127 122 118 116 118 124
19 120 118 126 128 122 129 126 118
20 126 127 129 132 127 122 118 118
21 132 136 132 130 134 130 126 120
22 130 132 127 122 118 115 117 119
23 118 126 125 124 121 122 118 118
24 128 127 130 126 122 119 122 126
25 124 128 124 127 126 118 116 112
26 135 138 143 142 136 130 124 123
27 130 132 130 124 122 116 114 114
28 126 124 129 124 129 132 124 126
29 120 126 129 130 126 124 118 117
30 118 124 127 128 126 125 118 116
GROUP B : DIASTOLIC BLOOD PRESSYRE:
S. No PRE B 5 min 10 min 15 min 20 min 30 min 45 min End
1 86 89 92 84 80 77 76 72
2 83 85 80 82 76 74 73 70
3 87 92 97 82 74 69 67 69
4 83 80 81 77 72 70 67 71
5 70 74 75 70 67 65 63 64
6 85 83 84 83 76 72 70 72
7 72 75 79 74 72 66 65 63
8 76 84 87 84 75 67 70 67
9 73 75 70 67 65 66 70 72
10 72 74 78 72 70 67 69 67
11 75 73 70 70 67 70 72 74
12 80 84 82 74 66 67 67 69
13 76 77 79 80 75 72 70 67
14 74 79 74 70 67 66 70 71
15 75 77 73 64 65 70 72 73
16 82 84 82 80 74 71 73 70
17 88 92 90 91 87 82 80 75
18 75 79 75 70 67 65 66 70
19 74 72 72 75 70 73 70 70
20 73 72 73 79 75 70 67 69
21 79 84 83 79 80 76 72 68
22 76 79 74 70 67 62 63 67
23 74 77 73 70 70 69 67 68
24 75 73 78 74 71 70 72 76
25 70 75 72 74 73 67 62 60
26 83 87 89 82 74 72 70 71
27 80 84 83 74 70 67 66 63
28 72 70 76 72 75 80 75 77
29 70 76 78 82 75 72 69 70
30 76 79 80 82 75 72 70 69
GROUP B: MEAN ARTERIAL PRESSURE:
S. No PRE B 5 min 10 min 15 min 20 min 30 min 45 min End
1 101.3 104.3 107.6 100 96.6 93.3 94 92
2 98.6 100.6 98.3 98 92.6 90.6 88.6 86
3 102.6 106.6 110.3 97.3 90 85.3 83.3 85.6
4 100.6 97.3 97.3 92.6 90 86.3 83.6 87.3
5 86 88 91.3 86.6 84 82 79.3 78.3
6 100 98 101.3 99.3 92 88.6 88 88
7 90 93 97.3 93.3 90.3 84 82.6 81
8 94 101.3 104.3 100 92 85.3 85.3 83
9 87.3 92 87.6 85 82.3 83 86.3 88.3
10 84 86.6 94 88.6 85 82.6 85 74.3
11 92 91.6 88.6 86.6 84.3 87 89 91.6
12 96 100 98 91 84 83.3 83 85.3
13 88 90.6 98 97.3 91.3 88.6 86 83.3
14 88.6 97.3 93.6 88.6 84.3 83 86.3 88.6
15 91.3 94.6 90.3 82.6 82.6 86.6 89.3 90.6
16 97 99.3 97.3 95.3 88.6 86 88 87
17 104 108.6 108 109.6 103.3 98.6 96.6 91.3
18 89.3 94.6 92.3 87.3 84 82 83.3 88
19 89.3 87.3 90 92.6 87.3 91.6 88.6 86
20 90.6 90.3 91.6 96.6 92.3 87.3 84 89.3
21 96.6 101.3 99.3 96 98 94 90 89.3
22 94 96.6 91.6 87.3 84 79.6 81 84.3
23 88.6 93.3 90.3 88 87 86.6 84 84.6
24 92.6 91 95.3 91.3 88 86.3 88.6 92.6
25 88 92.6 89.3 91.6 90.6 84 80 77.3
26 100.6 104 107 88.6 91.3 91.3 88 88.3
27 96.6 100 98.6 90.6 87.3 83.3 82 80
28 90 88 93.6 89.3 93 97.3 91.3 93.3
29 86.6 92.6 95 98 92 89.3 85.3 85.6
30 90 94 95.6 97.3 92 89.6 86 84.6
PROFORMA
PROSPECTIVE, RANDOMISED, SINGLE BLINDED, CONTROLLED
STUDY ON THE EFFECTIVENESS OF DEXAMETHASONE AS AN
ADJUVANT TO LOCAL ANESTHETIC MIXTURE IN PROVIDING
POSTOPERATIVE ANALGESIA FOR SUPRACLAVICULAR
BRACHIAL PLEXUS BLOCK
NAME :                       AGE : SEX :  I.P.No :
DIAGNOSIS : SURGERY PLANNED:
Group A/B Dose of Bupivacaine :
Dose of Dexamethasone:
PREOPERATIVE ASSESSMENT:
HISTORY:
CO-MORBID ILLNESS & TREATMENT DETAILS:
EFFORT TOLERANCE- _______ METS
H/O PREVIOUS SURGERY :
H/O DRUG ALLERGY :
GENERAL EXAMINATION:
HEIGHT:                                 WEIGHT:
ANAEMIA- JAUNDICE- PEDAL EDEMA -         AIRWAY-
PULSE- BP- CVS-         RS-
INVESTIGATIONS:
Hb : BT: CT: BLOOD GROUPING & TYPING:
BLOOD SUGAR: UREA: CREATININE:
ECG: CXR:
SUPRACLAVICULAR BLOCK :
Perivascular technique
PARAMETERS TO BE OBSERVED :
Time to achieve complete sensory blockade
Time to achieve complete motor blockade
Duration of analgesia
Onset of pain in the postoperative period
Onset of motor regression
Quality of analgesia using VAS score
INTRA OP VITAL PARAMETERS:
TIME PR SBP DBP SpO2 RR Side Effects
Base line
5 min
10 min
15 min
20 min
25 min
30 min
35 min
40 min
45 min
50 min
55 min
60 min
65 min
70 min
75 min
80 min
85 min
90 min
SIDE EFFECTS :
Side effects
Nausea / vomiting
Pruritis
Hypotension
Bradycardia
INTRA OP EVENTS:
IV FLUIDS :
CONVERSION TO GA :
QUALITY OF SURGICAL ANAESTHESIA :
EXCELLENT GOOD POOR
PAIN SCORE : (VERBAL RATING SCALE)
ENDING TIME : Onset of pain and motor regression in the postoperative
period
VAS SCALE
Visual Analog Scale (VAS)
  Very           Hurts just         Hurts a         Hurts even      Hurts a          Hurts as
Happy,        a little bit.        little more.           more.       Whole lot.    Much as you
no hurt.        can imagine
0              1         2         3         4        5         6        7        8        9        10
No pain                                                                                    Severe pain
